Lisa E. Porter

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Richard M. Bergenstal, Carol Wysham, Leigh MacConell et al. · The Lancet · 2010 · 605 citations

Medicine, Pharmacology, Pharmacotherapy +15

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

John B. Buse, Daniel J. Drucker, Kristin Taylor et al. · Diabetes Care · 2010 · 354 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

The Paradox of the Low-Renin State in Diabetic Nephropathy

Deborah A. Price, Lisa E. Porter, Michael Gordon et al. · Journal of the American Society of Nephrology · 1999 · 273 citations

Medicine, Endocrinology, Physiology +16

Rosiglitazone reduces urinary albumin excretion in type II diabetes

George L. Bakris, Giancarlo Viberti, Wayde M. Weston et al. · Journal of Human Hypertension · 2003 · 240 citations

Medicine, Pharmacology, Pharmacotherapy +14

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial

Rury R. Holman, Mary Angelyn Bethel, Jyothis T. George et al. · American Heart Journal · 2015 · 106 citations

Medicine, Cardiology, Pharmacology +14